Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,030.00 at TD Cowen

Regeneron Pharmaceuticals (NASDAQ:REGN) had its price target lifted by investment analysts at TD Cowen from $1,020.00 to $1,030.00 in a report issued on Wednesday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. TD Cowen’s price target indicates a potential upside of 13.24% from the company’s current price.

Several other brokerages have also issued reports on REGN. Morgan Stanley upped their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 13th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday. UBS Group boosted their price target on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research note on Wednesday, April 17th. Sanford C. Bernstein initiated coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 price target for the company. Finally, Royal Bank of Canada reiterated an “outperform” rating and issued a $1,189.00 price objective on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 9th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $977.77.

Regeneron Pharmaceuticals Price Performance

Shares of Regeneron Pharmaceuticals stock traded up $2.26 during trading on Wednesday, hitting $909.58. The stock had a trading volume of 162,977 shares, compared to its average volume of 486,978. The firm has a market cap of $99.84 billion, a price-to-earnings ratio of 26.17, a P/E/G ratio of 2.59 and a beta of 0.11. The company has a current ratio of 5.69, a quick ratio of 4.94 and a debt-to-equity ratio of 0.10. The business’s 50-day moving average is $951.41 and its 200 day moving average is $893.20. Regeneron Pharmaceuticals has a 12 month low of $684.80 and a 12 month high of $998.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Friday, February 2nd. The biopharmaceutical company reported $11.86 earnings per share for the quarter, beating the consensus estimate of $10.73 by $1.13. Regeneron Pharmaceuticals had a net margin of 30.14% and a return on equity of 17.61%. The firm had revenue of $3.43 billion for the quarter, compared to analysts’ expectations of $3.29 billion. During the same quarter last year, the company posted $10.96 EPS. The business’s quarterly revenue was up .6% on a year-over-year basis. As a group, sell-side analysts anticipate that Regeneron Pharmaceuticals will post 38.8 earnings per share for the current year.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction dated Tuesday, January 30th. The shares were sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the sale, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other Regeneron Pharmaceuticals news, EVP Andrew J. Murphy sold 5,783 shares of the stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $956.47, for a total value of $5,531,266.01. Following the transaction, the executive vice president now owns 48,306 shares of the company’s stock, valued at $46,203,239.82. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Bonnie L. Bassler sold 827 shares of the firm’s stock in a transaction that occurred on Tuesday, January 30th. The stock was sold at an average price of $959.00, for a total transaction of $793,093.00. Following the completion of the transaction, the director now directly owns 1,382 shares in the company, valued at approximately $1,325,338. The disclosure for this sale can be found here. Insiders have sold a total of 11,022 shares of company stock worth $10,552,991 in the last quarter. Corporate insiders own 8.83% of the company’s stock.

Institutional Trading of Regeneron Pharmaceuticals

Hedge funds have recently bought and sold shares of the stock. FMR LLC grew its stake in Regeneron Pharmaceuticals by 7.3% in the 3rd quarter. FMR LLC now owns 9,840,892 shares of the biopharmaceutical company’s stock worth $8,098,661,000 after acquiring an additional 669,517 shares in the last quarter. Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals by 0.5% in the fourth quarter. Vanguard Group Inc. now owns 8,838,285 shares of the biopharmaceutical company’s stock valued at $7,762,577,000 after buying an additional 39,780 shares during the last quarter. Capital World Investors raised its stake in shares of Regeneron Pharmaceuticals by 0.5% during the 4th quarter. Capital World Investors now owns 5,130,485 shares of the biopharmaceutical company’s stock valued at $4,506,071,000 after buying an additional 23,146 shares during the last quarter. Putnam Investments LLC lifted its stake in shares of Regeneron Pharmaceuticals by 2.1% in the 4th quarter. Putnam Investments LLC now owns 1,210,735 shares of the biopharmaceutical company’s stock valued at $1,063,377,000 after purchasing an additional 24,329 shares during the period. Finally, Northern Trust Corp grew its holdings in Regeneron Pharmaceuticals by 3.3% in the third quarter. Northern Trust Corp now owns 1,067,210 shares of the biopharmaceutical company’s stock valued at $878,271,000 after purchasing an additional 34,326 shares during the period. Hedge funds and other institutional investors own 83.31% of the company’s stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.